Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

254
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
254
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

499
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
499
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

622
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
622
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

558
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
558
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

659
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
659
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

127
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
127

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Journal Club: Cutaneous mosaicism: clinical patterns, genetic mechanisms, and practical implications for the dermatologist.

European journal of dermatology : EJD·2026
Same author

sQuiz your knowledge! Generalized papulo-nodular eruption in a patient with HIV.

European journal of dermatology : EJD·2026
Same author

Paediatric dermatology: prenatal chylothorax and capillary malformations: a clue to a genetic syndrome?

European journal of dermatology : EJD·2025
Same author

Woolly Hair: Essential Clue in Carvajal Syndrome.

International journal of trichology·2025
Same author

Journal club: Current and emerging biologic and targeted therapies for the treatment of hidradenitis suppurativa.

European journal of dermatology : EJD·2025
Same author

Journal club: Biomarkers for atopic dermatitis: current use and perspectives.

European journal of dermatology : EJD·2024
Same journal

Persistent generalized lymphadenopathy in a young woman: What is the diagnosis?

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same journal

Syndromic panels in critically ill pneumonia: beyond diagnosis.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same journal

Abdominal pain after a prolonged stay in the Brazilian Amazon: Contribution of molecular biology to etiological diagnosis.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same journal

Home based intravenous antimicrobial therapy in immunocompromised patients. Limited clinical success?

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same journal

Measles microbiological diagnosis in vaccinated persons: new times, new challenges.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same journal

Risk of tuberculosis infection according to exposure time and other factors of contacts and their index cases.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
See all related articles

Related Experiment Video

Updated: Aug 14, 2025

Imaging Corrosion at the Metal-Paint Interface Using Time-of-Flight Secondary Ion Mass Spectrometry
07:24

Imaging Corrosion at the Metal-Paint Interface Using Time-of-Flight Secondary Ion Mass Spectrometry

Published on: May 6, 2019

8.3K

Paint ulcers?

Elisa Hernández de la Torre-Ruiz1, Paloma García-Piqueras1, Clara Lacasta-Plasín1

  • 1Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|January 9, 2023
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation
07:16

Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation

Published on: June 16, 2023

2.0K
2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K

Related Experiment Videos

Last Updated: Aug 14, 2025

Imaging Corrosion at the Metal-Paint Interface Using Time-of-Flight Secondary Ion Mass Spectrometry
07:24

Imaging Corrosion at the Metal-Paint Interface Using Time-of-Flight Secondary Ion Mass Spectrometry

Published on: May 6, 2019

8.3K
Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation
07:16

Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation

Published on: June 16, 2023

2.0K
2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K